Cargando…
Association of programmed cell death ligand 1 and circulating lymphocytes with risk of venous thromboembolism in patients with glioma
INTRODUCTION: The role of the adaptive immune system in the pathophysiology of cancer-associated venous thromboembolism (VTE) has not been investigated in detail. Programmed cell death ligand 1 (PD-L1) is an immune checkpoint molecule responsible for immune evasion in several cancer entities, as exp...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7239522/ https://www.ncbi.nlm.nih.gov/pubmed/32424065 http://dx.doi.org/10.1136/esmoopen-2019-000647 |
_version_ | 1783536707607461888 |
---|---|
author | Mir Seyed Nazari, Pegah Berghoff, Anna S Preusser, Matthias Moik, Florian Posch, Florian Ricken, Gerda Riedl, Julia Hell, Lena Marosi, Christine Hainfellner, Johannes A Pabinger, Ingrid Ay, Cihan |
author_facet | Mir Seyed Nazari, Pegah Berghoff, Anna S Preusser, Matthias Moik, Florian Posch, Florian Ricken, Gerda Riedl, Julia Hell, Lena Marosi, Christine Hainfellner, Johannes A Pabinger, Ingrid Ay, Cihan |
author_sort | Mir Seyed Nazari, Pegah |
collection | PubMed |
description | INTRODUCTION: The role of the adaptive immune system in the pathophysiology of cancer-associated venous thromboembolism (VTE) has not been investigated in detail. Programmed cell death ligand 1 (PD-L1) is an immune checkpoint molecule responsible for immune evasion in several cancer entities, as expression on tumour cells silences the T cell-mediated immune response. Given the interrelation between inflammation, haemostasis and cancer, we aimed to investigate the association of players of the adaptive immunity (eg, lymphocytes, tumour PD-L1) with risk of VTE in patients with glioma, one of the most prothrombotic cancer types. METHODS: In this prospective observational single-centre cohort study, patients with newly diagnosed glioma or regrowth after resection were included. Primary endpoint was objectively confirmed VTE. At study inclusion, a blood draw was performed. Tumour PD-L1 expression was assessed via immunohistochemistry. RESULTS: In total, 193 patients were included. PD-L1 expression in ≥1% of tumour cells was observed in 20/193 (10.4%) glioma. In multivariable cox-regression analysis, on adjustment for age, sex and WHO grade IV, systemic lymphocyte counts were significantly associated with risk of VTE (HR per 1 G/L increase (95% CI): 1.15 (1.03 to 1.29), p=0.013). In contrast, no significant difference in risk of VTE was found regarding the PD-L1 status: the cumulative 24 months probability of VTE was 17.0% in patients with no PD-L1 and 11.8% in those with PD-L1 expressing tumours (p=0.663). CONCLUSION: In summary, PD-L1 expression was not associated with risk of VTE. Interestingly, peripheral lymphocytes, which are key players in adaptive immunity, were linked to an increased risk of glioma-associated VTE. |
format | Online Article Text |
id | pubmed-7239522 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-72395222020-05-28 Association of programmed cell death ligand 1 and circulating lymphocytes with risk of venous thromboembolism in patients with glioma Mir Seyed Nazari, Pegah Berghoff, Anna S Preusser, Matthias Moik, Florian Posch, Florian Ricken, Gerda Riedl, Julia Hell, Lena Marosi, Christine Hainfellner, Johannes A Pabinger, Ingrid Ay, Cihan ESMO Open Original Research INTRODUCTION: The role of the adaptive immune system in the pathophysiology of cancer-associated venous thromboembolism (VTE) has not been investigated in detail. Programmed cell death ligand 1 (PD-L1) is an immune checkpoint molecule responsible for immune evasion in several cancer entities, as expression on tumour cells silences the T cell-mediated immune response. Given the interrelation between inflammation, haemostasis and cancer, we aimed to investigate the association of players of the adaptive immunity (eg, lymphocytes, tumour PD-L1) with risk of VTE in patients with glioma, one of the most prothrombotic cancer types. METHODS: In this prospective observational single-centre cohort study, patients with newly diagnosed glioma or regrowth after resection were included. Primary endpoint was objectively confirmed VTE. At study inclusion, a blood draw was performed. Tumour PD-L1 expression was assessed via immunohistochemistry. RESULTS: In total, 193 patients were included. PD-L1 expression in ≥1% of tumour cells was observed in 20/193 (10.4%) glioma. In multivariable cox-regression analysis, on adjustment for age, sex and WHO grade IV, systemic lymphocyte counts were significantly associated with risk of VTE (HR per 1 G/L increase (95% CI): 1.15 (1.03 to 1.29), p=0.013). In contrast, no significant difference in risk of VTE was found regarding the PD-L1 status: the cumulative 24 months probability of VTE was 17.0% in patients with no PD-L1 and 11.8% in those with PD-L1 expressing tumours (p=0.663). CONCLUSION: In summary, PD-L1 expression was not associated with risk of VTE. Interestingly, peripheral lymphocytes, which are key players in adaptive immunity, were linked to an increased risk of glioma-associated VTE. BMJ Publishing Group 2020-05-17 /pmc/articles/PMC7239522/ /pubmed/32424065 http://dx.doi.org/10.1136/esmoopen-2019-000647 Text en © Author (s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ on behalf of the European Society for Medical Oncology. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, any changes made are indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/. |
spellingShingle | Original Research Mir Seyed Nazari, Pegah Berghoff, Anna S Preusser, Matthias Moik, Florian Posch, Florian Ricken, Gerda Riedl, Julia Hell, Lena Marosi, Christine Hainfellner, Johannes A Pabinger, Ingrid Ay, Cihan Association of programmed cell death ligand 1 and circulating lymphocytes with risk of venous thromboembolism in patients with glioma |
title | Association of programmed cell death ligand 1 and circulating lymphocytes with risk of venous thromboembolism in patients with glioma |
title_full | Association of programmed cell death ligand 1 and circulating lymphocytes with risk of venous thromboembolism in patients with glioma |
title_fullStr | Association of programmed cell death ligand 1 and circulating lymphocytes with risk of venous thromboembolism in patients with glioma |
title_full_unstemmed | Association of programmed cell death ligand 1 and circulating lymphocytes with risk of venous thromboembolism in patients with glioma |
title_short | Association of programmed cell death ligand 1 and circulating lymphocytes with risk of venous thromboembolism in patients with glioma |
title_sort | association of programmed cell death ligand 1 and circulating lymphocytes with risk of venous thromboembolism in patients with glioma |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7239522/ https://www.ncbi.nlm.nih.gov/pubmed/32424065 http://dx.doi.org/10.1136/esmoopen-2019-000647 |
work_keys_str_mv | AT mirseyednazaripegah associationofprogrammedcelldeathligand1andcirculatinglymphocyteswithriskofvenousthromboembolisminpatientswithglioma AT berghoffannas associationofprogrammedcelldeathligand1andcirculatinglymphocyteswithriskofvenousthromboembolisminpatientswithglioma AT preussermatthias associationofprogrammedcelldeathligand1andcirculatinglymphocyteswithriskofvenousthromboembolisminpatientswithglioma AT moikflorian associationofprogrammedcelldeathligand1andcirculatinglymphocyteswithriskofvenousthromboembolisminpatientswithglioma AT poschflorian associationofprogrammedcelldeathligand1andcirculatinglymphocyteswithriskofvenousthromboembolisminpatientswithglioma AT rickengerda associationofprogrammedcelldeathligand1andcirculatinglymphocyteswithriskofvenousthromboembolisminpatientswithglioma AT riedljulia associationofprogrammedcelldeathligand1andcirculatinglymphocyteswithriskofvenousthromboembolisminpatientswithglioma AT helllena associationofprogrammedcelldeathligand1andcirculatinglymphocyteswithriskofvenousthromboembolisminpatientswithglioma AT marosichristine associationofprogrammedcelldeathligand1andcirculatinglymphocyteswithriskofvenousthromboembolisminpatientswithglioma AT hainfellnerjohannesa associationofprogrammedcelldeathligand1andcirculatinglymphocyteswithriskofvenousthromboembolisminpatientswithglioma AT pabingeringrid associationofprogrammedcelldeathligand1andcirculatinglymphocyteswithriskofvenousthromboembolisminpatientswithglioma AT aycihan associationofprogrammedcelldeathligand1andcirculatinglymphocyteswithriskofvenousthromboembolisminpatientswithglioma |